血脉通颗粒治疗亚临床颈动脉粥样硬化(肾阴亏虚痰瘀互结证)的临床研究被引量：9

下载PDF

导出

摘要目的:观察血脉通颗粒对亚临床颈动脉粥样硬化的影响。方法:150例肾阴亏虚痰瘀互结证的亚临床颈动脉粥样硬化患者按2∶1随机分为血脉通颗粒组(100例)和阿托伐他汀组(50例),治疗6个月,观察血脂、CD14+CD16+细胞/单核细胞比例、hsCRP、TNF-α、IL-6、CIMT,斑块积分的变化。结果:1.中药调节血脂能力与西药相当,除HDL外两组间无显著性差异(P>0.05),两组TC、TG、LDL较治疗前下降有统计学意义(P<0.01),而降低TG、LP(a)方面中药优于西药(P<0.01)。2.两组炎症CD14+CD16+细胞/单核细胞、hsCRP、TNF-α与IL-6较治疗前下降有统计学意义(P<0.01),下调CD14+CD16+细胞/单核细胞及IL-6的作用中药优于西药(P<0.01);3.治疗后血脉通组CIMT较治疗前下降有统计学意义(P<0.01),西药组下降无统计学意义(P>0.05);两组斑块积分较治疗前显著下降(P<0.05),但两组间无显著性差异(P>0.05);4.中药组中医证素积分的改善比西药组更明显(P<0.01),且有效率优于西药组(P<0.05)。结论:血脉通颗粒能调节血脂,下调CD14+CD16+细胞和炎症因子,降低CIMT和斑块积分,而干预颈动脉粥样硬化进程,改善中医证素积分,提高生活质量。

作者蔡云张斌霞王紫逸张奕民张琪

机构地区南京中医药大学第一临床医学院常州市中医医院

出处《中药材》 CAS CSCD 北大核心 2014年第1期162-165,共4页 Journal of Chinese Medicinal Materials

基金江苏省自然科学基金项目(BK2010195)

关键词颈动脉粥样硬化血脉通颗粒阿托伐他汀 CD14+CD16+ 炎症因子

分类号 R972.6 [医药卫生—药品]

引文网络
相关文献

参考文献13

1The World Health Organization. Reducing risks, promoting healthy life [ R ]. The World Health Report ,2002.
2Gronholdt ML, Nordestgaard BG, Schroeder TV, et al. Ultra- sonic echolucent carotid plaques predict future strokes [ J ]. Circulation ,2001. 104:68-73.
3Lorenz MW, Markus HS, Bots ML,et al. Prediction of clini- cal cardiovascular events with carotid intima-media thick- ness-a systematic review and meta-analysis [ J ]. Circula- tion ,2007,115:459-467.
4O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group [ J ]. N Engl J Med, 1999,340 : 14-22.
5血管超声检查指南[J].中华超声影像学杂志,2009,18(10):911-920. 被引量：274
6Crouse JR, Harpold GH, Kahl FR, et al. Evaluation of a scoring system for extracranial carotid atherosclerosis extent with B-mode ultrasound [ J ]. Stroke, 1986,17:270-275.
7Yamada K, Yoshimura S, Kawasaki M, et al. Effects of Atorvastatin on Carotid Atherosclerotic Plaques: A Ran- domized Trial for Quantitative Tissue Characterization of Carotid Atherosclerotic Plaques with Integrated Backscatter Ultrasound [ J ]. Cerebrovasc Dis, 2009,28:417-424.
8Hansson GK. Inflammation, atherosclerosis, and coronary artery disease [ J ]. N Engl J Med,2005,352 :1685-1695.
9Ziegler-Heitbrock L. The CD14 * CD16 blood monocytes: their role in infection and inflammation [ J ]. J Leukoc Bi- ol,2007,81 : 584-592.
10Beige KU, Dayyani F, Horeh A, et al. The Proinflammatory CD14+ CD16 + DR++ Monocytes Are a Major Source of TNF [ J 1. J Immunol ,2002 ,168 : 3536-3542.